These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 2992782)
1. Brachial plexus neuropathy following high-dose cytarabine in acute monoblastic leukemia. Scherokman B; Filling-Katz MR; Tell D Cancer Treat Rep; 1985 Sep; 69(9):1005-6. PubMed ID: 2992782 [TBL] [Abstract][Full Text] [Related]
2. [Infiltrative peripheral neuropathy of acute monoblastic leukemia during hematologic remission]. Kishimoto N; Shimada H; Adachi M; Shiomura T; Kinoshita M; Harada K Rinsho Ketsueki; 1994 Sep; 35(9):876-80. PubMed ID: 7967057 [TBL] [Abstract][Full Text] [Related]
3. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology. Early AP; Preisler HD; Slocum H; Rustum YM Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642 [TBL] [Abstract][Full Text] [Related]
4. The value of combination therapy in adult acute myeloid leukemia with central nervous system involvement. Castagnola C; Nozza A; Corso A; Bernasconi C Haematologica; 1997; 82(5):577-80. PubMed ID: 9407724 [TBL] [Abstract][Full Text] [Related]
5. Peripheral neuropathy after high-dose cytosine arabinoside, daunorubicin, and asparaginase consolidation for acute nonlymphocytic leukemia. Powell BL; Capizzi RL; Lyerly ES; Cooper MR J Clin Oncol; 1986 Jan; 4(1):95-7. PubMed ID: 3001234 [TBL] [Abstract][Full Text] [Related]
6. [Painful legs and moving toes. Neuropathy caused by cytarabine]. Malapert D; Degos JD Rev Neurol (Paris); 1989; 145(12):869-71. PubMed ID: 2559449 [TBL] [Abstract][Full Text] [Related]
7. Acute polyneuropathy after high dose cytosine arabinoside in patients with leukemia. Openshaw H; Slatkin NE; Stein AS; Hinton DR; Forman SJ Cancer; 1996 Nov; 78(9):1899-905. PubMed ID: 8909309 [TBL] [Abstract][Full Text] [Related]
8. Brachial plexus neuropathy in the population of Rochester, Minnesota, 1970-1981. Beghi E; Kurland LT; Mulder DW; Nicolosi A Ann Neurol; 1985 Sep; 18(3):320-3. PubMed ID: 2996415 [TBL] [Abstract][Full Text] [Related]
9. Reversible posterior leukoencephalopathy syndrome after repeat intermediate-dose cytarabine chemotherapy in a patient with acute myeloid leukemia. Saito B; Nakamaki T; Nakashima H; Usui T; Hattori N; Kawakami K; Tomoyasu S Am J Hematol; 2007 Apr; 82(4):304-6. PubMed ID: 16947320 [TBL] [Abstract][Full Text] [Related]
10. Pharmacological study of modified intermediate-dose cytarabine therapy in patients with acute myeloid leukemia. Sutoh H; Yamauchi T; Gotoh N; Sugiyama M; Ueda T Anticancer Res; 2003; 23(6D):5037-42. PubMed ID: 14981964 [TBL] [Abstract][Full Text] [Related]
11. Peripheral neuropathy associated with high-dose Ara-C therapy. Borgeat A; De Muralt B; Stalder M Cancer; 1986 Aug; 58(4):852-4. PubMed ID: 3013396 [TBL] [Abstract][Full Text] [Related]
12. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. Yee KW; Cortes J; Ferrajoli A; Garcia-Manero G; Verstovsek S; Wierda W; Thomas D; Faderl S; King I; O'brien SM; Jeha S; Andreeff M; Cahill A; Sznol M; Giles FJ Leuk Res; 2006 Jul; 30(7):813-22. PubMed ID: 16478631 [TBL] [Abstract][Full Text] [Related]